Abstract 66P
Background
The use of molecular radionuclide therapy (MRT), such as targeted alpha therapy, is an emerging option for cancer treatment. The first alpha-emitter approved for therapeutic use was radium-223 (Ra-223), indicated for metastatic castration-resistant prostate cancer (mCRPC), with exclusive bone metastasis. However, treatment outcomes are below expectations. There are some limitations, such as precise dosimetry, that could be addressed to improve clinical outcomes. In fact, there is no inclusion of radiobiology and molecular dosimetry data obtained in preclinical studies into MRT planning as occur for radiotherapy. Moreover, there is a lack of these data for MRT. Thus, the aim of this study was to develop preclinical studies to access radiobiology and dosimetry for MRT, namely for Ra-223.
Methods
Preclinical studies were conducted using metastatic PCa cells or spheroids, to better mimic tumor architecture, as cellular models of mCRPC. Radiobiological endpoints, such as viability, survival and death, were measured 7days post-irradiation of cellular models with increasing activities of Ra-223 (0-7040 Bq/mL) for 24h. The size, geometry and cell distribution of each cellular model were analyzed by confocal microscopy and values were used in combination with radiobiological and kinetics endpoints to perform cell dosimetry using MIRDcell V3.
Results
The exposure to increasing activities of Ra-223 induces a decrease in viability, survival with increasing of cell death for both cellular models, with biological effects depending on the cell model characteristics. These effects are less evident when evaluated in spheroids, when exposed to the same activities of Ra-223. These biological data were validated with dosimetric calculations that confirm differences in absorbed doses depending not only on initial activity but also on cellular model characteristics.
Conclusions
The radiobiological and dosimetric studies showed that radiation effects for Ra-223 are dependent on molecular and structural characteristics of the cellular model, being the spheroids more representative of tumor architecture and better to conduct translational preclinical studies for MRT, as well as to obtain precise dosimetry.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was funded by the Foundation for Science And Technology (FCT), Portugal, through the Strategic Projects UIDB/04539/2020, UIDP/04539/2020, and by COMPETE-FEDER, reference number POCI-01-0145-FEDER-007440. Scholarship grants from FCT and European Social Funding to I.A.M. (SFRH/BD/136973/2018).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09